PMA device
Urolume(R) Endoprosthesis
Boston Scientific Corp · Stent, Urethral, Bulbous, Permanent Or Semi-Permanent (MES, Class III) · First FDA decision Feb 14, 2000, newest Jun 7, 2001Enlarged prostate (BPH)
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
0
Naming "Urolume Endoprosthesis"
MAUDE reports
2
Brand "Urolume Endoprosthesis", since 2015
PubMed studies
13
Mentioning "Urolume Endoprosthesis"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Urolume(R) Endoprosthesis
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- UROLUME(R) ENDOPROSTHESISPMA supplement
P920023-S014 · Decided Jun 7, 2001 · 171 days after receipt · Normal 180 Day Track
Device type: STENT, URETHRAL, BULBOUS, PERMANENT OR SEMI-PERMANENT (MES) · GI, Urology & Nephrology
- UROLUME ENDOPROSTHESISPMA supplement
P920023-S013 · Decided May 1, 2001 · 144 days after receipt · Normal 180 Day Track
Device type: STENT, URETHRAL, BULBOUS, PERMANENT OR SEMI-PERMANENT (MES) · GI, Urology & Nephrology
- UROLUME(R) ENDOPROSTHESISPMA supplement
P920023-S010 · Decided Feb 14, 2000 · 138 days after receipt · Normal 180 Day Track
Device type: STENT, URETHRAL, BULBOUS, PERMANENT OR SEMI-PERMANENT (MES) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Urolume Endoprosthesis", any status and sponsor, newest update first.
No registered device study names "Urolume Endoprosthesis".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Urolume Endoprosthesis", and for the whole product code for context.
This brand
2 reports: 0 malfunction, 2 injury, 0 death
Whole product code MES
3 reports: 1 malfunction, 2 injury, 0 death
Newest reports for this brand
BOSTON SCIENTIFIC - MINNETONKA
2183959-2017-00094 · Received Oct 10, 2017
Device type: Stent, Urethral, Bulbous, Permanent Or Semi-Permanent (MES)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Incontinence; Burning Sensation; Stenosis; Dysuria
2183959-2015-00403 · Received Sep 25, 2015 · Event dated Jul 1, 2015
Device type: Stent, Urethral, Bulbous, Permanent Or Semi-Permanent (MES)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Dysuria; No Code Available
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Urolume Endoprosthesis"[tiab]. The summary above synthesizes these.
- Removal of UroLume endoprosthesis: experience of the North American Study Group for detrusor-sphincter dyssynergia application.
Gajewski JB, Chancellor MB, Ackman CF, et al. · J Urol · 2000Multicenter Study, Research Support, Non-U.S. Gov't
- Experience with urethral stent explantation.
Shah DK, Kapoor R, Badlani GH · J Urol · 2003Multicenter Study
- The UroLume endoprosthesis: a summary of the European and North American experience.
Oesterling JE · Prog Clin Biol Res · 1994Clinical Trial, Multicenter Study
- Virtual optimization of self-expandable braided wire stents.
De Beule M, Van Cauter S, Mortier P, et al. · Med Eng Phys · 2009
- The UroLume endoprosthesis and UroLume cripple syndrome: a systematic review and meta-analysis of pathophysiology, complications, surgical management, psychological burden, and epidemiology of surviving patients worldwide.
Kapos IP · World J Urol · 2026Systematic Review, Meta-Analysis
- The surgical management of obstructive stents used for urethral strictures.
Elkassaby AA, Al-Kandari AM, Shokeir AA · J Urol · 2007
- 11-year outcome analysis of endourethral prosthesis for the treatment of recurrent bulbar urethral stricture.
Shah DK, Paul EM, Badlani GH · J Urol · 2003Multicenter Study
- Uncommon complications of permanent stents.
Corujo M, Badlani GH · J Endourol · 1998Case Reports
- [Our experience with the urolume intraurethral prosthesis].
García Peñalver C, Parra Escobar JL, Sánchez Blasco E · Arch Esp Urol · 2007English Abstract
- The North American experience with the UroLume endoprosthesis as a treatment for benign prostatic hyperplasia: long-term results. The North American UroLume Study Group.
Oesterling JE, Kaplan SA, Epstein HB, et al. · Urology · 1994Clinical Trial, Multicenter Study
- Removal of urolume endoprosthesis using holmium:YAG laser.
Kural AR, Tüfek I, Akpinar H, et al. · J Endourol · 2001Case Reports
- Extraction of UroLume endoprosthesis with one-stage urethral reconstruction using buccal mucosa.
Fisher MB, Santucci RA · Urology · 2006Case Reports
Other devices of this type
Also filed under product code MES.
- Ams Urolume EndoprosthesisBoston Scientific Corp · PMA 2011
- Urolume Endourethral Prosthesis for Prostatic Obstruction Secondary to Benign Prostatic HypertrophyBoston Scientific Corp · PMA 2004
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.